The Contribution and Perspectives of Proteomics to Epithelial Ovarian Cancer.

IF 2.1 4区生物学 Q3 BIOCHEMICAL RESEARCH METHODS

PROTEOMICS – Clinical Applications Pub Date : 2025-01-26 DOI:10.1002/prca.202300220

Jiayu Pei, Haifeng Qiu, Wenjia Wang, Yulu Wang, Min Wang, Dian Wang, Jing Li, Yanru Qin

{"title":"The Contribution and Perspectives of Proteomics to Epithelial Ovarian Cancer.","authors":"Jiayu Pei, Haifeng Qiu, Wenjia Wang, Yulu Wang, Min Wang, Dian Wang, Jing Li, Yanru Qin","doi":"10.1002/prca.202300220","DOIUrl":null,"url":null,"abstract":"<p><p>Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy which mainly consists of serous, mucinous, clear cell, and endometrioid subtypes. Due to the lack of classic symptoms at an early stage, EOC usually presented as advanced tumors with local and/or distant metastasis. Although a large portion of EOC was initially platinum-sensitive, most patients would acquire resistance to common chemotherapeutic agents. These aforementioned issues lead to a challenge for clinical treatments and unsatisfying outcomes. Previous studies have demonstrated the genetic features of EOC are hard to target and the alterations at DNA and RNA levels are not fully represented at the protein expression profiles which made it more complex. In recent years, a panel of studies attempted to explore the key proteins involved in the development and progression of EOC using high-throughput proteomic technologies. We herein summarized them to provide a full view of this topic. Trial Registration: ClinicalTrials.gov identifier: NCT046698990.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e202300220"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/prca.202300220","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy which mainly consists of serous, mucinous, clear cell, and endometrioid subtypes. Due to the lack of classic symptoms at an early stage, EOC usually presented as advanced tumors with local and/or distant metastasis. Although a large portion of EOC was initially platinum-sensitive, most patients would acquire resistance to common chemotherapeutic agents. These aforementioned issues lead to a challenge for clinical treatments and unsatisfying outcomes. Previous studies have demonstrated the genetic features of EOC are hard to target and the alterations at DNA and RNA levels are not fully represented at the protein expression profiles which made it more complex. In recent years, a panel of studies attempted to explore the key proteins involved in the development and progression of EOC using high-throughput proteomic technologies. We herein summarized them to provide a full view of this topic. Trial Registration: ClinicalTrials.gov identifier: NCT046698990.

查看原文本刊更多论文

上皮性卵巢癌（EOC）是致死率最高的妇科恶性肿瘤，主要包括浆液性、粘液性、透明细胞性和子宫内膜样亚型。由于早期缺乏典型症状，EOC 通常表现为有局部和/或远处转移的晚期肿瘤。虽然大部分 EOC 最初对铂类药物敏感，但大多数患者会对普通化疗药物产生耐药性。上述问题导致临床治疗面临挑战，疗效不尽人意。以往的研究表明，EOC 的遗传特征很难被靶向，DNA 和 RNA 水平的改变并不能完全体现在蛋白质表达谱上，这使其变得更加复杂。近年来，一系列研究试图利用高通量蛋白质组学技术探索参与 EOC 发生和发展的关键蛋白质。在此，我们对这些研究进行了总结，以全面了解这一课题。试验注册：ClinicalTrials.gov 标识符：NCT046698990：NCT046698990。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PROTEOMICS – Clinical Applications 医学-生化研究方法

CiteScore

5.20

自引率

5.00%

发文量

审稿时长

1 months

期刊介绍： PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including: -basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease -the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers -the use of proteomics for the discovery of novel drug targets -the application of proteomics in the drug development pipeline -the use of proteomics as a component of clinical trials.